Medscape_Oncology_whiteout

Redefining the Patient Journey

The Promise and Practice in NTRK Fusion-Positive Cancers CME

Hilton Chicago

Sunday, May 31, 2026 | 6:30 pm - 8:00 pm CT

Hybrid

Supported by an independent educational grant from Bayer.

overview

Join us in Chicago for an interactive activity on [italic]NTRK[/italic] fusions that equips clinicians with actionable knowledge to optimize personalized care across the patient journey. Using expert-led updates, case-based discussions, patient perspectives, and audience polling, learners will review the latest tumor-agnostic clinical data and guideline recommendations, sharpen best practices for molecular testing to reliably detect [italic]NTRK[/italic] gene fusions, and apply strategies to tailor treatment decisions for adult and pediatric patients. An emphasis on multidisciplinary collaboration and practical workflow integration will increase clinicians’ competence and confidence in coordinating care. Participants will complete the program prepared to implement evidence-based testing and management approaches to improve outcomes for patients with [italic]NTRK[/italic] fusion-positive cancers.

Not an official event of the 2026 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer® the ASCO Foundation.

faculty

agenda

6:00 PM CT

6:30 PM CT

6:40 PM CT

7:00 PM CT

7:25 PM CT

7:50 PM CT

8:00 PM CT

location

Hilton Chicago

720 S Michigan Ave, Chicago, Illinois, 60605

Room: International Ballroom South (2nd Floor)

target audience

This educational activity is intended for an international audience oncologists, pathologists, pulmonologists, pediatricians, endocrinologists, and members of the entire oncology care team.

goal statement

The goal of this activity is for learners to be better able to apply the latest clinical data and guidelines across the patient journey to optimize personalized care.

learning objectives

[bold]Upon completion of this activity, participants will:[/bold] [para]Have increased knowledge regarding the[/para] [list][item]Latest clinical data of tumor-agnostic treatment for [italic]NTRK[/italic] fusion-positive cancers [/list] [para]Have greater competence related to[/para] [list][item]Best practices for molecular testing to detect [italic]NTRK[/italic] gene fusions [item]Tailoring treatment for patients with [italic]NTRK[/italic] fusion-positive cancers [/list] [para]Demonstrate greater confidence in their ability to[/para] [list][item]Work effectively in the multidisciplinary team to optimize the management of [italic]NTRK[/italic] fusion-positive cancers [/list]

accreditation statement

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

accreditation logo
medscape logo
[title]For Physicians[/title] [text]Medscape, LLC designates this live activity for a maximum of 1.5 [bold][italic]AMA PRA Category 1 Credit(s)[/italic][super]TM[/super][/bold]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.[/text]